TNFA -308G>A and IL10 -1082A>G polymorphisms seem to be predictive biomarkers of chronic HCV infection

Abstract

Background Genetic changes may induce dysregulated cytokine production and affect the progression of the chronic disease caused by the hepacivirus C (HCV) because the balance of pro- and anti-inflammatory cytokines determines the outcome of infection. This study evaluated the TNFA -308G>A and IL10 -1082A>G polymorphisms in the susceptibility and progress of chronic hepatitis C. Method The study included 101 samples from patients with chronic hepatitis C and 300 samples from healthy donors. Polymorphisms were typed by real-time PCR and were analyzed for associations with histopathological parameters (according to METAVIR classification) and HCV viral load. Results The polymorphic genotype for the TNFA -308G>A variant was not present in the group of patients with chronic hepatitis C and its absence could be associated with protection against HCV infection (p = 0.0477). Patients with the polymorphic genotype of the IL10 -1082A>G polymorphism had higher HCV viral load than wild-type patients (p = 0.0428). Neither polymorphism was associated with different levels of necroinflammatory activity or fibrosis scores. Conclusion Our results suggest the polymorphic genotype at TNFA -308G>A as protective against chronic HCV infection, and the polymorphic genotype at the IL10 -1082A>G variant associated with higher HCV viral load. Further studies must be performed in order to confirm these associations.

Association of Tumor Necrosis Factor-Alpha (TNF-α) and Suppressor of Cytokine Signaling-1 (SOCS-1) Gene Variants in Children with COVID-19

“…In our study, the high expression-related CA / Del genotype and CA allele were found to be significantly higher in COVID-19 patients, which can be evaluated as related to increased SOCS-1 expression and decreased anti-viral cytokine release. In a study from 2021, 14 the efficacy of the TNF-α-308G > A variant was evaluated in patients with hepatitis C virus (HCV), and it was shown that the GA genotype was protective against HCV infection but had no effect on necro-inflammatory activity or fibrosis score. Current findings show that the TNF-α gene variant distribution was not different between the patient and healthy groups.…”

“…In a study from 2021, 14 the efficacy of the TNF-α-308G > A variant was evaluated in patients with hepatitis C virus (HCV), and it was shown that the GA genotype was protective against HCV infection but had no effect on necro-inflammatory activity or fibrosis score. Current findings show that the TNF-α gene variant distribution was not different between the patient and healthy groups.…”

“…(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) Journal of Pediatric Infectious Diseases Vol 18. No.…”

Association of the IFNG +874T/A Polymorphism with Symptomatic COVID-19 Susceptibility

“…Thus, we used the genotypic and allelic frequencies described in the control samples of these studies as representative of the population of Belem (control group, CG) and used them for comparisons with our sample. Three studies were used for the TNF -308G/A polymorphism [ 20 , 21 , 22 ] with a total of 497 individuals, while for the IFNG +874T/A polymorphism, we used two studies [ 22 , 23 ] with a total of 397 individuals.…”

The Effect of Treatment-Induced Viral Eradication on Cytokine and Growth Factor Expression in Chronic Hepatitis C

“…Inflammatory responses caused by HCV infection can cause progressive liver disease. Some inflammatory cytokines may serve as biomarkers for monitoring disease progression and treatment outcome in patients with CHC [ 10 ]. The pathogenesis of HCV-infected patients is complicated and includes classical pathogen recognition, inflammatory activation, intrahepatic inflammatory cascade response, oxidative stress and endoplasmic reticulum stress.…”